Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Technologies, Partek Partner on End-to-End Bioinformatics Workflow

NEW YORK ─ Partek said Thursday that it has entered into an agreement with Santa Clara, California-based Agilent Technologies to integrate its Partek Flow bioinformatics software with the Agilent Alissa Clinical Informatics platform, providing an end-to-end analysis workflow that is customizable for Agilent's customers.

According to St. Louis-based Partek, it has made available the Agilent pipeline for RNA-seq inside Partek Flow, enabling Agilent to resell Partek Flow software through the Agilent Alissa portal.

Financial and other terms of the agreement were not disclosed.

"As next-generation sequencing is more broadly adopted for clinical applications, our customers' software requirements are also expanding," Kevin Meldrum, vice president and general manager of Agilent's Genomics Division, said in a statement. "By integrating Partek Flow with the Agilent Alissa Clinical Informatics Platform, we will strengthen our overall offering to address diverse applications and workflows across the translational research to clinical testing continuum."

With the integration of the bioinformatics software and clinical informatics platform, Partek Flow automatically processes and analyzes data in the background, and then passes results to the Agilent Alissa Interpret platform where the results are combined into a report. The integration enables clinical decision support and the identification of genetic signatures of disease in the clinical setting, as well as secondary analysis and the use of visualization tools for both DNA and RNA applications, Partek said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.